PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 26, 2026Hematology0 citationsOpen Access

XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia

View Full Paper
CXChunli XuHebei Medical UniversityDWDandan WangWannan Medical CollegeRCRuiqi ChenWannan Medical College

Key Points

  • This research aims to explore the therapeutic potential of Selinexor in targeting homologous recombination in acute myeloid leukemia through the XPO1-E2F7 pathway.
  • Investigated the effects of Selinexor on the XPO1-E2F7-HR axis in acute myeloid leukemia cells.
  • Analyzed the influence of E2F7 nuclear export on homologous recombination efficiency.
  • Integrated Selinexor with DNA-damaging agents to assess combined treatment efficacy.
  • Selinexor significantly inhibits E2F7 nuclear export, resulting in reduced homologous recombination activity.
  • Combination treatment with Selinexor and DNA-damaging agents enhances therapeutic outcomes in AML models.

Abstract

The XPO1-E2F7-HR axis represents a potential therapeutic vulnerability, supporting the rational combination of Selinexor with DNA-damaging agents to improve AML treatment outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xu et al. (2026) studied this question.

synapsesocial.com/papers/69edacdb4a46254e215b48b3https://doi.org/10.1080/16078454.2026.2664314
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selinexor in multiple myeloma2024 · 14 citations
  2. 2Novel agents in relapsed/refractory diffuse large B‐cell lymphoma2023 · 18 citations
  3. 3A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma2022 · 4 citations
  4. 4PCAF-mediated acetylation regulates RAD51 dynamic localization on chromatin during HR repair2025 · 2 citations
  5. 5Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia2023 · 13 citations